



(51) International Patent Classification:

C12P 19/30 (2006.01) A23L 1/30 (2006.01)
C12P 19/34 (2006.01) C12N 1/06 (2006.01)

(21) International Application Number:

PCT/EP2012/052545

(22) International Filing Date:

15 February 2012 (15.02.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11154867.3 17 February 2011 (17.02.2011) EP
61/443,900 17 February 2011 (17.02.2011) US

(71) Applicant (for all designated States except US): **DSM IP ASSETS B.V.** [NL/NL]; Het Overloon 1, NL-6411 TE Heerlen (NL).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **NOORDAM, Bertus** [NL/NL]; P.O. Box 130, NL-6100 AC Echt (NL).

(74) Agents: **MISSET, Onno** et al.; DSM Intellectual Property, P.O. Box 130, NL-6100 AC Echt (NL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PROCESS FOR THE PRODUCTION OF A COMPOSITION CONTAINING 5'-RIBONUCLEOTIDES

(57) Abstract: The present invention describes a process comprising a) subjecting a microorganism to autolysis under conditions at which a substantial part of the RNA remains in a form degradable into 5-ribonucleotides; b) subjecting the autolysate to solid/liquid separation and recovering the RNA-containing cell wall fraction; and c) converting the RNA in the recovered RNA-containing cell wall fraction into 5-ribonucleotides, whereby the solid/liquid separation in step b) is done at a pH of lower than 5.1. Said process is simple and allows for the production of a very pure composition of 5'-ribonucleotides. It also allows for the production of a very clear yeast extract.

